Can Adjuvant HPV Vaccination Be Helpful in the Prevention of Persistent/Recurrent Cervical Dysplasia after Surgical Treatment?—A Literature Review

• Published in: Cancers Vol. 14; no. 18; p. 4352
• Main Authors: Michalczyk, Kaja, Misiek, Marcin, Chudecka-Głaz, Anita
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.09.2022; MDPI
• Subjects: Age; Biopsy; Cancer screening; Care and treatment; Cell growth; Cervical cancer; Cervix; Cervix dysplasia; Colposcopy; Disease prevention; Diseases; DNA methylation; Dysplasia; Genomes; Human papillomavirus; Infections; Lesions; Literature reviews; Medical screening; Mortality; Patient outcomes; Patients; Proteins; Relapse; Review; Tumor necrosis factor-TNF; Vaccines; Viral infections; Viruses; Womens health; Poland
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14184352

Cervical cancer formation is preceded by precursor lesions, including low-grade squamous intraepithelial lesions (LSILs) and high-grade squamous intraepithelial lesions (HSILs), which are usually diagnosed in women of reproductive age. Despite the recent advanced diagnostic and treatment methods, including colposcopy, the loop electrosurgical excision procedure (LEEP), and surgical conization, the recurrence or residual disease affects as many as 6.6% of patients. The lesions are often associated with human papilloma virus (HPV) infection. As HPV persistence is the leading and only modifiable factor affecting the risk of progression of CIN lesions into high-grade cervical dysplasia and cancer, it has been proposed to conduct adjuvant vaccination in patients treated for high-grade cervical dysplasia. To date, no vaccine has been approved for therapeutic use in patients diagnosed with HSILs; however, attempts have been made to determine the use of HPV prophylactic vaccination to reduce recurrent HSILs and prevent cervical cancer. The aim of this review was to analyze the up-to-date literature concerning the possible use of secondary human papilloma virus (HPV) vaccination as an adjuvant method to surgical treatment in patients diagnosed with cervical HSILs. Adjuvant HPV vaccination after surgical treatment may reduce the risk of recurrent cervical dysplasia.